Advertisement

Antiepileptika

  • P. Clarenbach
  • W. Fröscher

Zusammenfassung

Den Antiepileptika ist definitionsgemäß eine Eigenschaft gemein: die Unterdrückung der Ausbreitung paroxysmaler, synchroner zerebraler Entladung. Da die klinisch relevanten Antiepileptika unterschiedlichen chemischen Gruppen angehören, wird dieses Ziel auf unterschiedlichen Wegen erreicht, was sich in unterschiedlichem Verhalten in tierexperimentellen Epilepsiemodellen und damit unterschiedlichen klinischen Indikationen niederschlägt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Booker HE (1989) Trimethadione. In: Levy R et al. (eds) Antiepileptic drugs. Raven Press, New York, pp 715–720Google Scholar
  2. Browne TR (1989) Methsuximide. In: Levy RH et al. (eds) Antiepileptic drugs, 3rd ed. Raven Press, New York, pp 707–714Google Scholar
  3. Browne TR, Greenblatt DJ, Evans JE, Evans BA, Szabo GK, Schumacher GE (1987) Estimation of a drug’s elimination half life at any serum concentration when the drug’s Km and Vmax are known: calculation and validation with phenytoin. J Clin Pharmacol 27: 318–320PubMedGoogle Scholar
  4. Clarenbach P, Fröscher W (1986) Indikationen der Benzodiazepin-Antikonvulsiva. In: Hippius H, Engel RR (Eds) Therapie mit Benzodiazepinen — Rückblick und Ausblick. Springer, Berlin Heidelberg New York Tokyo, S 195–200Google Scholar
  5. Coulter DA, Huguenard JR, Price DA (1988) Antivonvulsants depress calcium spikes and calcium currents of mammalian thalamic neurons in vitro. Soc Neurosci Abstr 14: 644Google Scholar
  6. Commission on Classification and Terminology of the International League Against Epilepsy (1981) Proposal for revised clinical and electroencephalographic classifications of epileptic seizures. Epilepsia 22: 489–501CrossRefGoogle Scholar
  7. Commission for Classification of Epilepsies and Epileptic Syndromes (1985) Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 26: 268–278CrossRefGoogle Scholar
  8. Cramer JA, Mattson, RH, Bennett DM, Swick CT (1986) Variable free and total valproic acid concentrations in sole and multi drug therapy. Ther Drug Monit 8: 411–416PubMedCrossRefGoogle Scholar
  9. Doose H (1989) Epilepsien im Kindes-und Ju- gendalter, 9. Aufl. Desitin-Werk, HamburgGoogle Scholar
  10. Dreifuss E (1989) Bromides. In: Levy RH et al. (eds) Antiepileptic drugs, 3rd ed. Raven Press, New York, pp 877–886Google Scholar
  11. Editorial (1986) Official names of antiepileptic drugs. Epilepsia 27: 311CrossRefGoogle Scholar
  12. Ferendelli JA, Holland KD (1989) Ethosuximid. Mechanisms of action. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE (eds) Antiepileptic drugs. Raven Press, New York, pp 653–661Google Scholar
  13. Fichsel H (1991) Auswahl der Antiepileptika — Kindes-und Jugendalter. In: Fröscher W, Vassella F (Eds) Die Epilepsien. De Gruyter, Berlin New YorkGoogle Scholar
  14. Frey HH (1988) Wirkungsmechanismen von Antiepileptika. In: Walden J, Speckmann EJ (Eds) Elementarprozesse epileptischer Anfälle und Grundlagen der medikamentösen Epilepsietherapie. Zuckschwerdt, München Bern Wien San Francisco, S 43–53Google Scholar
  15. Frey HH, Löscher W (1978) Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17: 637–642PubMedCrossRefGoogle Scholar
  16. Fröscher W (1976) Therapie des Status epilepticus. Schattauer, Stuttgart New YorkGoogle Scholar
  17. Fröscher W (1979) Treatment of status epilepticus. University Park Press, BaltimoreGoogle Scholar
  18. Fröscher W (1980) Tabellen zur Pharmakotherapie der Epilepsien unter besonderer Berücksichtigung pharmakokinetischer Gesichtspunkte. In: Fröscher W et al. (Eds) Medikamentöse Therapie der Epilepsien unter Kontrolle der Antiepileptika-Serumspiegel. Schattauer, Stuttgart New York, S 267–389Google Scholar
  19. Fröscher W (1983) Indikationen der Therapie mit Antiepileptika. Therapie bei speziellen Anfallsformen. In: Langer G, Heimann H (Eds) Psychopharmaka. Springer, Wien New York, S 375–379Google Scholar
  20. Fröscher W (1990a) Epilepsien. In: FRÖSCHER W (Eds) Lehrbuch der Neurologie. De Gruyter, Berlin New York, S 579–631Google Scholar
  21. Fröscher W (1990b) Medikamentöse Therapie der Epilepsien. Fortschr Med 108: 77–81PubMedGoogle Scholar
  22. Fröscher W, Rambeck B (1983) Klinische Pharmakologie und Pharmakokinetik der Antiepileptika. In: Langer G, Heimann H (Eds) Psychopharmaka. Springer, Wien New York, S 360–367Google Scholar
  23. Fröscher W, Klenk W, Penin H, Schultheiss R, Stefan H (1984) Der therapieresistente Status epilepticus. In: Meier-Ewert K (Eds) Therapieresistenz bei Anfallsleiden. Zuckschwerdt, München Bern Wien, S 42–52Google Scholar
  24. Fromm G, Glass JD, Chattha AS, Martinez AJ (1981) Effect of anticonvulsant drugs on inhibitory and excitatory pathways. Epilepsia 22: 65–73PubMedCrossRefGoogle Scholar
  25. Goggin T, Callaghan N (1986) Blood levels of clobazam and its metabolites and therapeutic effect. In: Hindmarch I et al. (eds) Clobazam: human psychopharmacology and clinical application. The Royal Society of Medicine, London, pp 149–153Google Scholar
  26. Gram L (1989) Lamotrigin. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE (eds) Antiepileptic drugs. Raven Press, New York, pp 947–953Google Scholar
  27. Janz D (1969) Die Epilepsien. Thieme, StuttgartGoogle Scholar
  28. Koella WP (1986) Time-related variations in po- tency and efficacy in rats with repeated admi- nistration of anticonvulsants. In: Frey HH et al. (eds) Tolerance to beneficial and adverse effects of antiepileptic drugs. Raven Press, New York, pp 81–86Google Scholar
  29. Koeppen D (1985) A review of clobazam studies in epilepsy. In: Hindmarch I et al. (eds) Clobazam: human psychopharmacology and clinical applications. The Royal Society of Medicine, London, pp 207–215Google Scholar
  30. Kramer G, Fröscher W (1988) Antiepileptische Pharmakotherapie im Erwachsenenalter: Was sind die derzeitigen Mittel erster Wahl? Akt Neurol 15: 189–194CrossRefGoogle Scholar
  31. Löscher W (1981) Valproate induced changes in GABA metabolism at the subcellular level. Biochem Biopharmacol 30: 1364–1366CrossRefGoogle Scholar
  32. Macdonald RL, Barker JL (1979) Enhancement of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: a common mode of anticonvulsant action. Brain Res 167: 323–336PubMedCrossRefGoogle Scholar
  33. Macdonald RL, Maclean MJ (1986) Anticonvulsant drugs: mechanisms of action. In: Delgado-Esqueta AV et al. (eds) Basic mechanisms of the epilepsies. Molecular and cellular approaches. Raven Press, New York, pp 713–736 (Adv Neurol, vol 44 )Google Scholar
  34. Matrhes A (1984) Epilepsie, 4. Aufl. Thieme, Stuttgart New YorkGoogle Scholar
  35. Nau H, Löscher W (1982) Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and y-aminobutyric acid ( GABA) metabolism in the mouse. J Pharmacol Exp Ther 220: 654–659Google Scholar
  36. Olsen RW (1982) Drug interactions at the GABA receptor-ionophor complex. Ann Rev Pharmacol Toxicol 22: 245–277CrossRefGoogle Scholar
  37. Reynolds EH, Milner G, Matthews DM, Chanarin I (1966) Anticonvulsant therapy, megaloblastic haemopoiesis and folic acid metabolism. Quart J Med 35: 521–537Google Scholar
  38. Schmidt B (1989) Potential antiepileptic drugs: gabapentin. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE(eds) Antiepileptic drugs. Raven Press, New York, pp 925–935Google Scholar
  39. Shorvon SD (1989) Benzodiazepines: clobazam. In: Levy RH et al. (eds) Antiepileptic drugs, 3rd ed. Raven Press, New York, pp 821–840Google Scholar
  40. Skerrirr JH, Macdonald RL (1984) Benzodiazepine receptor ligand actions on GABA responses: benzodiazepines, Cl 218–872, zopiclone. Eur J Pharmacol 101: 127–134CrossRefGoogle Scholar
  41. Skerritf JH, Werz MA, Mclean MJ, Macdonald RL (1984) Diazepam and its anomalous p-chloro derivative Ro 5–4864. Comparative effects on mouse neurons in cell culture. Brain Res 310: 99–105Google Scholar
  42. Stenzel E (1987) Valproat-Therapie and Lebertoxizität. Internist Prax 27: 361–365Google Scholar
  43. Woodbury DM, Kemp JW (1989) Sulfonamides and derivatives: acetazolamide. In: Levy RH et al. (eds) Antiepileptic drugs, 3rd ed. Raven Press, New York, pp 855–875Google Scholar
  44. Zavadil P, Gallagher BB (1976) Metabolism and excretion of 14C-primidone in epileptic patients. In: Janz D (ed) Epileptology. Thieme, Stuttgart New York, pp 129–139Google Scholar

Copyright information

© Springer-Verlag Wien 1992

Authors and Affiliations

  • P. Clarenbach
  • W. Fröscher

There are no affiliations available

Personalised recommendations